NewsRx

Search our medical news database

Access Pharmaceuticals, Inc.

Tumor therapy developer completes $5M convertible offering

Published in Lab Business Week, March 12th, 2006

Access Pharmaceuticals, Inc. (AKCA) announced that it has completed an offering of 7.5% convertible notes due March 31, 2007 and common stock warrants, resulting in gross proceeds of $5.0 million.

The notes and warrants were sold in a private placement to a group of investors led by SCO Capital Partners LLC.

The notes mature on March 31, 2007, are convertible into company common stock at a fixed conversion rate of $0.22 per share, bear interest of 7.5% per annum and are secured by the assets of the company. The notes may be converted at the option of the holders or the company under certain circumstances as defined in the notes.

...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook